202 related articles for article (PubMed ID: 37733174)
1. Reirradiation versus systemic therapy versus combination therapy for recurrent high-grade glioma: a systematic review and meta-analysis of survival and toxicity.
Marwah R; Xing D; Squire T; Soon YY; Gan HK; Ng SP
J Neurooncol; 2023 Sep; 164(3):505-524. PubMed ID: 37733174
[TBL] [Abstract][Full Text] [Related]
2. Salvage systemic therapy for advanced gastric and oesophago-gastric junction adenocarcinoma.
Tomita Y; Moldovan M; Chang Lee R; Hsieh AH; Townsend A; Price T
Cochrane Database Syst Rev; 2020 Nov; 11(11):CD012078. PubMed ID: 33210731
[TBL] [Abstract][Full Text] [Related]
3. Radiotherapy versus combination radiotherapy-bevacizumab for the treatment of recurrent high-grade glioma: a systematic review.
Kulinich DP; Sheppard JP; Nguyen T; Kondajji AM; Unterberger A; Duong C; Enomoto A; Patel K; Yang I
Acta Neurochir (Wien); 2021 Jul; 163(7):1921-1934. PubMed ID: 33796887
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience.
Kline C; Liu SJ; Duriseti S; Banerjee A; Nicolaides T; Raber S; Gupta N; Haas-Kogan D; Braunstein S; Mueller S
J Neurooncol; 2018 Dec; 140(3):629-638. PubMed ID: 30206764
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
[TBL] [Abstract][Full Text] [Related]
8. Outcome of Second Line Treatment of Recurrent High- Grade Glioma by re-Irradiation or Bevacizumab-based Chemotherapy: A Cross Sectional Study.
Anvari K; Shahabadi M; Welsh JS; Javadinia SA; Zarei E
Asian Pac J Cancer Prev; 2023 May; 24(5):1507-1511. PubMed ID: 37247269
[TBL] [Abstract][Full Text] [Related]
9. Anti-angiogenic therapy for high-grade glioma.
Ameratunga M; Pavlakis N; Wheeler H; Grant R; Simes J; Khasraw M
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008218. PubMed ID: 30480778
[TBL] [Abstract][Full Text] [Related]
10. Multiple drug combinations of bortezomib, lenalidomide, and thalidomide for first-line treatment in adults with transplant-ineligible multiple myeloma: a network meta-analysis.
Piechotta V; Jakob T; Langer P; Monsef I; Scheid C; Estcourt LJ; Ocheni S; Theurich S; Kuhr K; Scheckel B; Adams A; Skoetz N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31765002
[TBL] [Abstract][Full Text] [Related]
11. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer.
Chuai Y; Rizzuto I; Zhang X; Li Y; Dai G; Otter SJ; Bharathan R; Stewart A; Wang A
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD013348. PubMed ID: 33661538
[TBL] [Abstract][Full Text] [Related]
12. Antiangiogenic therapy for high-grade glioma.
Khasraw M; Ameratunga MS; Grant R; Wheeler H; Pavlakis N
Cochrane Database Syst Rev; 2014 Sep; (9):CD008218. PubMed ID: 25242542
[TBL] [Abstract][Full Text] [Related]
13. Treatment of newly diagnosed glioblastoma in the elderly: a network meta-analysis.
Hanna C; Lawrie TA; Rogozińska E; Kernohan A; Jefferies S; Bulbeck H; Ali UM; Robinson T; Grant R
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD013261. PubMed ID: 32202316
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Proton Therapy Reirradiation for Patients With Recurrent Head and Neck Squamous Cell Carcinoma.
Lee A; Woods R; Mahfouz A; Kitpanit S; Cartano O; Mohamed N; Youssef I; Marqueen K; Sine K; Mah D; Neal B; Zakeri K; Kang JJ; Riaz N; Yu Y; McBride SM; Chen LD; Tsai CJ; Gelblum DY; Press RH; Michel LS; Sherman EJ; Pfister D; Dunn LA; Ho AL; Fetten J; Wong RJ; Boyle JO; Singh B; Cracchiolo JR; Ganly I; Cohen MA; Lee NY
JAMA Netw Open; 2023 Jan; 6(1):e2250607. PubMed ID: 36689229
[TBL] [Abstract][Full Text] [Related]
15. Radiation and subsequent reirradiation outcomes in the treatment of diffuse intrinsic pontine glioma and a systematic review of the reirradiation literature.
Freese C; Takiar V; Fouladi M; DeWire M; Breneman J; Pater L
Pract Radiat Oncol; 2017; 7(2):86-92. PubMed ID: 28274399
[TBL] [Abstract][Full Text] [Related]
16. Interventions for the treatment of brain radionecrosis after radiotherapy or radiosurgery.
Chung C; Bryant A; Brown PD
Cochrane Database Syst Rev; 2018 Jul; 7(7):CD011492. PubMed ID: 29987845
[TBL] [Abstract][Full Text] [Related]
17. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
Chen Y; Guo L; Li X; Liu R; Ren C; Du S
Clin Neurol Neurosurg; 2020 Nov; 198():106239. PubMed ID: 33007724
[TBL] [Abstract][Full Text] [Related]
18. Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer.
Yegya-Raman N; Berman AT; Ciunci CA; Friedes C; Berlin E; Iocolano M; Wang X; Lai C; Levin WP; Cengel KA; O'Reilly SE; Cohen RB; Aggarwal C; Marmarelis ME; Singh AP; Sun L; Bradley JD; Plastaras JP; Simone CB; Langer CJ; Feigenberg SJ
Int J Radiat Oncol Biol Phys; 2024 May; 119(1):56-65. PubMed ID: 37652303
[TBL] [Abstract][Full Text] [Related]
19. Systematic assessment of clinical outcomes and toxicities of proton radiotherapy for reirradiation.
Verma V; Rwigema JM; Malyapa RS; Regine WF; Simone CB
Radiother Oncol; 2017 Oct; 125(1):21-30. PubMed ID: 28941560
[TBL] [Abstract][Full Text] [Related]
20. Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.
Patel A; Kalachand R; Busschots S; Doherty B; Kapros E; Lawlor D; Hall N; Stordal BK
Cochrane Database Syst Rev; 2022 Jul; 7(7):CD008766. PubMed ID: 35866378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
